In an op-ed in Forbes, Eli Lilly’s President and CEO John Lechleiter, sounds an alarming warning about the spread of multi-drug resistant tuberculosis and gives a passionate call for financial support of The Global Fund to Fight AIDS, Tuberculosis and Malaria.
The Global Fund, which funds programs to combat HIV, TB and malaria in low-income countries, is the midst of its fourth major fundraising effort, or replenishment, targeting $15 billion over the next three years.
“It is absolutely critical to ensure that the Global Fund is fully funded in order to prevent drug resistance from undermining the gains we’ve made against TB, and to keep us on track to get all three of these diseases under control,” Lechleiter wrote. “Taking our eye off the ball now would imperil future generations and result in significantly higher health care costs for governments around the world.”
Lechleiter also pointed to public-private partnerships as a key tool in fighting the three diseases. He cited 40 partnerships involving the pharmaceutical industry that target TB, including the Lilly MDR-TB Partnership, which is focused on training healthcare professionals to identify and treat drug-resistant TB, and increasing access to quality assured second-line TB drugs.
“We must fully fund the Global Fund, find new and better treatments, and seek creative solutions through innovative public-private partnerships,” Lechleiter wrote.